Yeo Jue Byun1, Sung Jun Lee, Hyoung Jun Koh. 1. Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
Abstract
PURPOSE: To identify fluorescein angiography (FA) and optical coherence tomography (OCT) characteristics predicting responses to intravitreal bevacizumab therapy in patients with neovascular age-related macular degeneration (AMD). METHODS: Results of 113 consecutive patients (113 eyes) treated with intravitreal bevacizumab injections for neovascular AMD were retrospectively reviewed. Patients were categorized into two groups according to visual acuity (VA) improvement 1 year after treatment: responders and nonresponders. Responders were defined as patients who achieved VA improvement ≥7 Early Treatment Diabetic Retinopathy Study (ETDRS) letters for occult choroidal neovascularization (CNV), and ≥11 ETDRS letters for classic CNV at month 12. N onresponders were defined as patients who did not meet the above VA improvement at month 12. RESULTS: Of the 113 eyes, 36 (31.9%) were categorized as responders and 77 (68.1%) as nonresponders. Nonresponders, compared with responders, had thicker subretinal tissue (SRT) (218.9 μm versus 180.9 μm, P = 0.040), and more frequent cystoid macular edema (CME) (42.9% versus 13.9%, P < 0.001). CONCLUSION: Thick SRT and CME on OCT may be characteristic of nonresponders and may be helpful for tailoring treatment for neovascular AMD.
PURPOSE: To identify fluorescein angiography (FA) and optical coherence tomography (OCT) characteristics predicting responses to intravitreal bevacizumab therapy in patients with neovascular age-related macular degeneration (AMD). METHODS: Results of 113 consecutive patients (113 eyes) treated with intravitreal bevacizumab injections for neovascular AMD were retrospectively reviewed. Patients were categorized into two groups according to visual acuity (VA) improvement 1 year after treatment: responders and nonresponders. Responders were defined as patients who achieved VA improvement ≥7 Early Treatment Diabetic Retinopathy Study (ETDRS) letters for occult choroidal neovascularization (CNV), and ≥11 ETDRS letters for classic CNV at month 12. N onresponders were defined as patients who did not meet the above VA improvement at month 12. RESULTS: Of the 113 eyes, 36 (31.9%) were categorized as responders and 77 (68.1%) as nonresponders. Nonresponders, compared with responders, had thicker subretinal tissue (SRT) (218.9 μm versus 180.9 μm, P = 0.040), and more frequent cystoid macular edema (CME) (42.9% versus 13.9%, P < 0.001). CONCLUSION: Thick SRT and CME on OCT may be characteristic of nonresponders and may be helpful for tailoring treatment for neovascular AMD.
Authors: Hajir Dadgostar; Alexandre A C M Ventura; Jeffrey Y Chung; Sumit Sharma; Peter K Kaiser Journal: Ophthalmology Date: 2009-07-29 Impact factor: 12.079
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: David B Rein; Ping Zhang; Kathleen E Wirth; Paul P Lee; Thomas J Hoerger; Nancy McCall; Ronald Klein; James M Tielsch; Sandeep Vijan; Jinan Saaddine Journal: Arch Ophthalmol Date: 2006-12
Authors: Gennady Landa; Wendewessen Amde; Vatsal Doshi; Amro Ali; Laura McGevna; Ronald C Gentile; Thomas O Muldoon; Joseph B Walsh; Richard B Rosen Journal: Ophthalmologica Date: 2009-07-08 Impact factor: 3.250
Authors: Sandra Joeres; Jerry W Tsong; Paul G Updike; Allyson T Collins; Laurie Dustin; Alexander C Walsh; Peggy W Romano; SriniVas R Sadda Journal: Invest Ophthalmol Vis Sci Date: 2007-09 Impact factor: 4.799
Authors: Miltiadis K Tsilimbaris; Maria I López-Gálvez; Roberto Gallego-Pinazo; Philippe Margaron; George N Lambrou Journal: J Ophthalmol Date: 2016-03-17 Impact factor: 1.909
Authors: Chris M Pappas; Moussa A Zouache; Stacie Matthews; Caitlin D Faust; Jill L Hageman; Brandi L Williams; Burt T Richards; Gregory S Hageman Journal: Hum Genomics Date: 2021-09-25 Impact factor: 4.639